Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+ Industry Domains
Report
Press Release
Blogs
Industry Statistics
Add 2 More Reports For 20% off

Report Overview

The bronchodilators market size was valued at USD 30.65 Billion in 2025, driven by the rising incidence of chronic lung diseases like COPD and asthma across the globe. The market is expected to grow at a CAGR of 4.60% during the forecast period of 2026-2035, with the values likely to rise from USD 48.06 Billion by 2035.

2025

Base Year

2019-2025

Historical Period

2026-2035

Forecast Period

Compound Annual Growth Rate

4.6%

Value in USD Billion

2026-2035


*this image is indicative*

Bronchodilators: Introduction

A bronchodilator is a medication that helps in the relaxation of the muscles around the bronchi, facilitating easy breathing. It is usually used to relieve the symptoms of asthma, COPD (chronic obstructive pulmonary disease) and other lung diseases. A bronchodilator helps clean the mucus from lungs, allowing it to move freely and get out of the body easily.

There are two forms, mainly short-acting bronchodilators that are effective for 3-6 hours while long-acting bronchodilators that provide help up to 12 hours. They are available as inhalers and nebulizers.

Bronchodilators Market Analysis

With the emergence of COVID-19, the bodies have become more susceptible to chronic respiratory illnesses. β2 adrenoceptor agonists bronchodilators have also found their application as an alternative treatment for treating COVID infected patients, as a result, bronchodilators market demand has seen an upswing in the historic period.

The incidence of chronic lung diseases has led to an increased demand for quality treatment for patients. Bronchodilators are still widely used to treat both COPD and asthma, hence, there have been several new advancements in the existing technology. A contemporary approach to formulate a new dual bronchodilator therapy is in the works. This drug class called MABA has both mAChR antagonism and β2-agonist activity in one molecule. It is believed to be better than the existing combinations due to its ‘triple therapy’ (treatment alternative for COPD) feature. The MABA Batefenterol is under an advanced clinical development stage.

Bronchodilator drugs are also used in combinations to treat lung diseases. For instance, AstraZenenca got the first and only asthma exacerbation risk reducing medication Airsupra (PT027) approved by the FDA in January 2023.It is the first ever drug that contains a combination of albuterol (β2 adrenergic agonist) and budesonide (corticosteroid). With increased application and demand, it is a clear indicator that bronchodilator market growth is certain in the upcoming years.

Bronchodilators Market Segmentation

"Bronchodilators Market Report and Forecast 2026-2035" offers a detailed analysis of the market based on the following segments:

Market Breakup by Drug Class

  • Beta-Adrenergic Bronchodilators
  • Xanthine Derivatives
  • Anticholinergic Bronchodilators
  • Others

Market Breakup by Indication

  • Asthma
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Allergic Reactions
  • Breathing Problem
  • Others

Market Breakup by Route of Administration

  • Oral
  • Parenteral
  • Inhalational
  • Others

Market Breakup by End User

  • Hospitals
  • Speciality Clinics
  • Home Healthcare
  • Others

Market Breakup by Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

Bronchodilators Market Overview

It is estimated that over 300 million asthma patients carry the burden of high morbidities and mortalities across the world. As a result, the bronchodilator market value has risen, with the vision to mitigate the number of morbidities associated with chronic respiratory diseases. The Asia Pacific region is expected to experience rapid growth in terms of market share owing to the presence of a geriatric population in the region. As a precautionary measure, the governments are more alert and working regularly by setting up several awareness campaigns.

The United States is anticipated to lead the bronchodilator market share, which is influenced by the existence of several healthcare leaders in the area. United States healthcare industry is always thriving to bring new innovations in the market. For instance, in a recent trial, Sanofi's Dupixent® showcased significant clinical potential to reduce COPD aggravations by 30%. This indicates that the country is set to experience the latest technological advances exclusively.

Bronchodilators Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

  • Bayer AG
  • Teva Pharmaceutical Industries Ltd. 
  • Sun Pharmaceutical Industries Ltd. 
  • Hikma Pharmaceutical PLC 
  • Amneal Pharmaceuticals LLC 
  • Aurobindo Pharma 
  • Johnsons & Johnsons Services Pvt Ltd 
  • GSK Plc 
  • Thermo Fisher Scientific Inc. 
  • Siemens 
  • Cipla Inc. 
  • AstraZeneca 
  • Mylan N.V.

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*

Looking for specific insights?

Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!

Key Questions Answered in the Report

The market attained a value of about USD 30.65 Billion in 2025, driven by the prevalence of chronic respiratory diseases like asthma and COPD across the globe.

The market is anticipated to grow at a CAGR of 4.60% during the forecast period of 2026-2035, likely to reach a market value of USD 48.06 Billion by 2035.

After the sudden outbreak of COVID-19, bronchodilators are widely used to treat COVID-19 infected people as well. Hence, the market demand has increased.

Several new technology MABA bronchodilators, like Batefenterol, are under advanced clinical trials. They are used being in combination drug treatments for asthma as well. AstraZenenca’s Airsupra (PT027) got the FDA approval in January 2023.

The major regions of the market include North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. North America is currently leading the global market.

The indications include asthma, chronic obstructive pulmonary disease (COPD), allergic reactions, and breathing problem, among others.

Bronchodilators by drug class include beta-adrenergic bronchodilators, xanthine derivatives, and anticholinergic bronchodilators, among others.

The route of administration can be oral, parenteral, and inhalational, among others.

The end users in the market are hospitals, specialty clinics, and home healthcare, among others.

Key players involved in the market are Bayer AG, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Hikma Pharmaceutical PLC, Amneal Pharmaceuticals LLC, Aurobindo Pharma, Johnsons & Johnsons Services Pvt Ltd, GSK Plc, Thermo Fisher Scientific Inc., Siemens, Cipla Inc., Mylan N.V., and AstraZeneca.

Report Summary

Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.

Key Highlights of the Report

Please note that the figures mentioned in the description serve as estimates and may vary from the actual figures presented in the final report.

REPORT FEATURES DETAILS
Base Year 2025
Historical Period 2019-2025
Forecast Period 2026-2035
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Type
  • Indication
  • Route of Administration
  • End User
  • Region
Breakup by Type
  • Beta-Adrenergic Bronchodilators 
  • Xanthine Derivatives 
  • Anticholinergic Bronchodilators
  • Others
Breakup by Indication
  • Asthma 
  • Chronic Obstructive Pulmonary Disease (COPD) 
  • Allergic Reactions 
  • Breathing Problem 
  • Others
Breakup by Route of Administration
  • Oral 
  • Parenteral 
  • Inhalational 
  • Others
Breakup by End User
  • Hospitals 
  • Speciality Clinics
  • Home Healthcare
  • Others
Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • PESTEL Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Company News and Developments
    • Certifications
Companies Covered
  • Bayer AG
  • Teva Pharmaceutical Industries Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Hikma Pharmaceutical PLC
  • Amneal Pharmaceuticals LLC
  • Aurobindo Pharma
  • Johnsons & Johnsons Services Pvt Ltd
  • GSK Plc
  • Thermo Fisher Scientific Inc.
  • Siemens
  • Cipla Inc.
  • AstraZeneca
  • Mylan N.V.

Datasheet

10 % Off

USD

3,299

2,969

Single User License

10 % Off

USD

5,499

4,949

Five User License

15 % Off

USD

6,999

5,949

Corporate License

15 % Off

USD

8,199

6,969

Datasheet

One User

USD 3,299

USD 2,969

tax inclusive*

  • Selected Segments
  • Printing Restrictions
  • Excel Spreadsheet Delivered via Email
  • Full Report
  • Periodic Updates
  • Post Sales Analysts Support
  • Unlimited Prints

Single User License

One User

USD 5,499

USD 4,949

tax inclusive*

  • All Segments
  • Printing Restrictions
  • PDF Delivered via Email
  • Custom Report Layout
  • Post Sales Analysts Support
  • Periodic Updates
  • Unlimited Prints

Five User License

Five User

USD 6,999

USD 5,949

tax inclusive*

  • All Segments
  • Five Prints Available
  • PDF Delivered via Email
  • Limited Free Customization
  • Post Sales Analyst Support
  • Custom Report Layout
  • Periodic Updates
  • Unlimited Prints

Corporate License

Unlimited Users

USD 8,199

USD 6,969

tax inclusive*

  • All Segments
  • Unlimited Prints Available
  • PDF & Excel Delivery via Email
  • Limited Free Customization
  • Post Sales Analysts Support
  • Discount On Next Update
  • Custom Report Layout

*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*

Bundle Type

Flash Bundle

20% OFF Number of Reports: 3

Small Business Bundle

25% OFF Number of Reports: 5

Growth Bundle

30% OFF Number of Reports: 8

Enterprise Bundle

35% OFF Number of Reports: 10
Overview
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 80 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 100 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards

*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*

Flash Bundle

Number of Reports: 3

20%

tax inclusive*

  • 3 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • Complimentary Excel Data Set
  • PPT Version of the Report
  • Power BI Dashboards
  • License Upgrade
  • Free Analyst Hours

Small Business Bundle

Number of Reports: 5

25%

tax inclusive*

  • 5 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • Complimentary Excel Data Set
  • PPT Version of the Report
  • Power BI Dashboards
  • License Upgrade

Growth Bundle

Number of Reports: 8

30%

tax inclusive*

  • 8 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • License Upgrade
  • Free Analyst Hours - 80 Hours
  • Power BI Dashboards

Enterprise Bundle

Number of Reports: 10

35%

tax inclusive*

  • 10 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • License Upgrade
  • Power BI Dashboards
  • Free Analyst Hours - 100 Hours

How To Order

This is a collaborative report by Vishakha Agrawal reflecting perspectives and research-driven insights from Expert Market Research.

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

License Type

Select License Type

Choose the right license for your needs and access rights.

shopping cart

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Strategic Solutions for Informed Decision-Making

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

We’re here to help answer any questions about our products and services.

Contact us